Objective To compare the effects of bortezomib combined with dexamethasone(BD) regimen and bortezomib combined with epirubicin and dexamethasone(PAD) regimen on patients' survival status and safety in the treatment of multiple myeloma.
Methods From January 2018 to March 2021, 80 patients with multiple myeloma were retrospectively selected, and divided into the BD group(42 cases) and PAD group(38 cases) according to the treatment plan.The therapeutic effect, serum indexes before and after treatment, survival status and adverse reactions were compared between two groups.
Results There was no statistical significance in the levels of hemoglobin, serum creatinine, β microglobulin, bone marrow plasma cell ratio and M protein before treatment, and levels of bone marrow plasma cells ratio and overall survival after treatment between two groups(P>0.05).After treatment, the hemoglobin levels in two groups increased, and the hemoglobin in the PAD group was higher than that in BD group(P < 0.05).After treatment, the serum creatinine, β microglobulin, bone marrow plasma cell ratio and M protein in two groups decreased(P < 0.05), and the levels of serum creatinine, β microglobulin and M protein in the PAD group decreased significantly compared with the BD group(P < 0.05).The total effective rate in the PAD group was 86.84%, which was higher than that in BD group(64.29%) (P < 0.05), and the progression-free survival in the PAD group was longer than that in BD group(P < 0.05).The difference of total adverse reaction rate of thrombocytopenia, granulocytopenia, mucositis, and numbness of hands and feet difference of was not statistically significant between PAD group and BD group(P>0.05).
Conclusions In the treatment of multiple myeloma, there is no significant difference in the adverse reactions between PAD regimen and BD regimen.The PAD regimen has better therapeutic effect, longer progression-free survival and fewer adverse reactions.
DownLoad: